CD4 as AIDS trials endpoint
Executive Summary
Role of CD4 will be addressed along with other laboratory markers as indicators of clinical benefit at the Anti-Viral Drugs Advisory Committee meeting scheduled for Feb. 13. On Feb. 14, the committee will examine follow-up trials of Burrough Wellcome's Retrovir (zidovudine) in patients with moderately symptomatic and asymptomatic diseases. Meeting will be held at Holiday Inn Crowne Plaza, Plaza II Room, Rockville, Maryland, beginning at 8:30 a.m. both days.